Concert Pharmaceuticals, Inc. announced today the presentation of data from a preclinical study demonstrating the potential of CTP-347, its novel deuterium-containing serotonin modulator, to avoid the risk of adverse drug-drug interactions when co-administered with tamoxifen, a widely-used breast cancer drug. These data were the subject of a poster presentation at the North American Menopause Society's 2008 Annual Meeting.
More...